作者简介
张志仁
主任医师,教授,博士生导师。龙江学者特聘教授,龙江名医。现任黑龙江省医学科学院代谢疾病研究所所长,哈尔滨医科大学附属肿瘤医院科研/外事主管领导、心内科主任。先后在哈医大、美国Emory大学和美国南卡州立医科大学从事心内科诊疗和科研工作38年。研究方向:离子通道功能在高血压中的作用及机制;心肌肥厚与重构;肿瘤心脏病的发生机制及防治。在J Hepatol, Hypertension, Diabetes, J Am Soc Nephrol, BJP, JAHA等杂志上发表SCI收录论文66篇,单篇最高影响因子14。主持和参加973子课题各1项,国家自然科学基金4项(其中重点国际合作项目1项,面上项目3项),教育部博士点基金(博导类)1项,省自然基金重点项目1项,黑龙江省教育厅海外学人资助项目1项,资助金总额1300余万元,获得黑龙江省科学技术一等奖。
担任中国抗癌协会整合肿瘤心脏病学分会主任委员、中华医学会临床药学分会常委、中国医师协会心血管内科医师分会常委、中国医师协会心血管内科医师分会肿瘤心脏病学专委会副主任委员;中华医学会心血管病学分会肿瘤心脏病学组副组长、中国药理学会心血管药理分会常委;黑龙江省医学会临床药学分会及肿瘤心脏病学分会主任委员等。担任Frontiers in Integrative and Regenerative Pharmacology杂志副主编,Frontiers in Renal and Epithelial Physiology和Pflugers Arch-Eur J Physiol杂志编委。
2019年肿瘤心脏病学领域
新进展盘点
李慧妍,邵群,张志仁
哈尔滨医科大学附属肿瘤医院心内科
黑龙江省肿瘤心脏病学诊疗中心
01
儿童肿瘤幸存者的心血管并发症
1.1儿童肿瘤幸存者蒽环类药物相关心脏毒性
1.2儿童肿瘤幸存者放疗相关心血管并发症
02
抗肿瘤治疗引起心脏毒性的早期评估
2.1心脏磁共振(cardiac magnetic resonance,CMR)
2.2超声心动图
03
乳腺癌患者曲妥珠单抗心脏毒性的一级预防
04
肺癌患者心脏照射剂量与预后
05
免疫检查点抑制剂的心脏毒性及管理
06
奥西替尼心脏毒性更强
07
新型口服抗凝药应用进展
7.1新型口服抗凝药预防肿瘤相关性静脉血栓
7.2新型口服抗凝药治疗肿瘤相关性静脉血栓
7.3新型口服抗凝药在指南中的地位
08
沙库巴曲缬沙坦用于肿瘤合并心力衰竭者
1.Wang Xuexia, Chen Yanjun, Hageman L, et al. Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report[J]. J Clin Oncol, 2019 ,37(suppl; abstr 10015).
2.Purnima Singh, Xuexia Wang, Lindsey Hageman, et al. A NOVEL ASSOCIATION BETWEEN GSTM1 NULL VARIANT AND ANTHRACYCLINE-INDUCED CARDIAC DYSFUNCTION (ACD) IN CHILDHOOD CANCER SURVIVORS (CCS): A COG ALTE03N1 REPORT. 2019 ASCO Annual meeting,Abstract NO:10030.
3.Bates JE,Howell RM,Liu Q,et al. Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. J Clin Oncol.2019,37(13):1090-1101.
4.Daniel Mulrooney,Geehong Hyun, Kirsten Ness, et al. Cardiac events in survivors of childhood cancer treated in more recent eras: A report from the Childhood Cancer Survivor Study. Journal of Clinical Oncology ,2019,37(15_suppl):10058-10058.
5.Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 2017;70:2536-2551.
6.Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, et al. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology,2019,73(7):779-791.
7.Jan Leerink, Heleen van der Pal, Elizabeth Feijen, et al.THE VALUE OF LEFT VENTRICULAR EJECTION FRACTION AT FIRST LONG-TERM FOLLOW-UP ECHOCARDIOGRAM IN THE SCREENING FOR CARDIOMYOPATHY IN LONG-TERM SURVIVORS OF CHILDHOOD CANCER. 2019 ASCO Annual meeting,Abstract.
8.Abir Khan,Omid Amidi,Kenneth R.Hess,et al.Defining cardiotoxicity of doxorubicin and trastuzumab. Journal of Clinical Oncology,2019,37(15):suppl.e23097.
9.Guglin M,Krischer J,Tamura R,et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol.2019,73(22):2859-2868.
10.Calvillo-Argüelles O,Abdel-Qadir H,Michalowska M,et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Can J Cardiol.2019,35(2):153-159.
11.Lynce F,Barac A,Geng X,et al.Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.Breast Cancer Res Treat.2019,175(3):595-603.
12.Hussain Y,Drill E,Dang CT,et al. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. Breast Cancer Res Treat.2019 ,175(1):239-246.
13.Atkins KM,Rawal B,Chaunzwa TL,et al. Cardiac Radiation Dose,Cardiac Disease,and Mortality in Patients With Lung Cancer. J Am Coll Cardiol.2019,73(23):2976-2987.
14.Master SR,Robinson A,Mills GM,et al. Cardiovascular complications of immune checkpoint inhibitor therapy.J Clin Oncol,2019,37(15):suppl;abstr 2568.
15.NCCN Clinical Practice Guidelines in Oncology:Management of Immunotherapy-Related Toxicities(Version 2.2019).
16.Esfahani K,Buhlaiga N,Thébault P,et al.Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.N Engl J Med.2019,380(24):2375-2376.
17.Salem JE,Allenbach Y,Vozy A,et al.Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. N Engl J Med.2019,380(24):2377-2379.
18.Kartik Anand, Joe Ensor, Barry ,et al. Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS).2019 ASCO Annual meeting,Abstract,NO:9044.
19.Khorana, AA,Soff GA,Kakkar AK,et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med.2019,380(8):720-728.
20.Carrier M,Abou-Nassar K,Mallick R,et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med.2019,380(8):711-719.
21.Raskob GE,van Es N,Verhamme P,et al.Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.N Engl J Med.2018,378(7):615-624.
22.Young AM,Marshall A,Thirlwall J,et al.Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).J Clin Oncol.2018,36(20):2017-2023.
23.McBane RD,Wysokinski WE,Le-Rademacher JG,et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost.2019 Oct 20.
24.Streiff MB,Holmstrom B,Angelini D,et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2019.
25.Key NS,Khorana AA,Kuderer NM,et al.Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.J Clin Oncol.2019 Aug 5:JCO1901461.
26.Wang TF,Zwicker JI,Ay C,et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH.J Thromb Haemost.2019 Oct ;17(10):1772-1778.
27.Farge D,Frere C,Connors JM,et al.2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Lancet Oncol.2019 Oct ;20(10):e566-e581.
28.中国临床肿瘤学会肿瘤与血栓专家委员会。肿瘤相关静脉血栓栓塞症预防与治疗指南 (2019版)。中国肿瘤临床,2019,46(13):653-660。
29.A Martin Garcia,C Mitroi,M Chaparro,et al. Is sacubitril/valsartan useful in patients with cancer and heart failure? Data from HF-COH spanish multicenter registry.2019 ESC Poster Session:P687.
联系客服